Release date: 2016-11-22 In July 2014, Google X Labs announced a partnership with Swiss pharmaceutical company Novartis to develop a smart contact lens. This kind of glasses can monitor the patient's blood sugar level, so that patients can avoid the pain of blood test, and also help patients with presbyopia and myopia, to provide them with more natural eye focus. At that time, people felt that this technology was like a dream, so there were still many people who questioned the project. Just in 2015, Novartis Pharmaceuticals CEO Joe Jimenez said that he will conduct human clinical testing in 2016. More than a year has passed. Today, Novartis Pharmaceuticals announced that the smart contact lenses they developed with Google are progressing steadily, but this year they can't start clinical testing. In addition, the glasses can provide patients with "autofocus." "The function will not currently appear in the research plan. According to the original plan, the smart contact lens can provide the patient with blood glucose level data once per second through the electronic technology of sensors, microchips and micro-batteries, so as to realize real-time monitoring of the patient's blood sugar level and can be connected to the insulin pump. Provide a suitable dose of insulin based on the blood glucose level per second. More similar to the role of an artificial pancreas. In addition, the focal length can be automatically adjusted according to the difference in human visual distance, helping the user to restore vision. At the time of the glasses, Novartis CEO Joseph Jimenez said that the smart contact lenses are likely to be available in 2019. However, since 2014, Novartis's turnover in the Alcon division, which focuses on eye health, has started to decline, so that the rumors that the department will be sold continue, but this has not affected the company's investment in innovative projects, Novartis also said to promote Innovative technologies such as smart lenses are a key part of Alcon's growth strategy. Although the ticket does not know what the reason is, it is obvious that the research and development of smart glasses is not as "stable progress" as Novartis said. When the smart glasses will be listed in the future, it seems that it is still unknown. Source: Zhao Qinghui Epitalon,Amidate,Raw Epitalon Powder,Bodybuilding Epitalon Shaanxi Hongbaiyi Biotech Co., Ltd. , https://www.sxhongbaiyi.com